Navigation Links
YM BioSciences granted two US patents for AeroLEF(R)
Date:2/10/2010

- Additional AeroLEF patents granted in Europe, China and other territories -

MISSISSAUGA, ON, Feb. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024. The Company also announced that AeroLEF's patent estate has expanded to include other territories with the issuance of European patent number 1,603,533 and several patent allowances in China, India, Mexico and other territories.

"These patents strengthen and extend the patent protection for AeroLEF in the US, and also expand the global market for this unique and potentially first in class product," said David Allan, CEO of YM BioSciences. "The scientific pedigree and unique advantages of this product have been established and its safety and efficacy have been demonstrated in numerous clinical trials. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally."

US patent number 7,648,981 protects the self-medicating method of pain management in which the pain sufferer inhales a formulation comprising free and liposomal fentanyl in a dose ratio that provides rapid onset and sustained relief from pain without attendant toxicity. Also claimed is a breath-actuated device for delivering the fentanyl formulation.

US patent numb
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Pittcon marketing department is pleased ... exposition mobile app, Pittcon 2015 . ... App Store for iOS and Android devices and the ... during and after the event. It acts as an ... technical sessions, Conferee Networking sessions and short courses. , ...
(Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 Theravalues ... Super sur le marché européen au salon Hi ... Amsterdam ). Curcumine la ... une technologie amorphe (non-cristalline) à des ingrédients approuvés ... est un pigment jaune présent dans la racine ...
(Date:11/26/2014)... , Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Piper Jaffray  26 th Annual Healthcare Conference ... be held at The New York Palace in ... presentation, material information concerning the Company, its operations, strategies and ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... Restriction Digests of DNA Isolated with the Perfectprep , ... , , , George Halley, Eppendorf 5 Prime, ... Introduction , Agarose gel electrophoresis is used ... used for downstream applications. Eppendorfs , Perfectprep Gel Cleanup kit ...
...
Eppendorf UVette Material Compatibility , , , , , , , , , , , , , , KEY: , AStable after 24 hours , BProperties of UVett...
Cached Biology Technology:Restriction Digests of DNA Isolated with the Perfectprep , Gel Cleanup Kit 2Restriction Digests of DNA Isolated with the Perfectprep , Gel Cleanup Kit 3Restriction Digests of DNA Isolated with the Perfectprep , Gel Cleanup Kit 4Restriction Digests of DNA Isolated with the Perfectprep , Gel Cleanup Kit 5
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... 2011 (Rome, Italy) -- Researchers speaking in the second ... Pathogenesis, Treatment and Prevention (IAS 2011) have today provided ... and alerted delegates to the challenges that developing countries ... antiretroviral therapy (ART) coverage. The presentations reflect the ...
... Small-scale fisheries could pose a more serious threat to ... University of Exeter, published today (19 July) in the ... shows that tens of thousands of turtles from across ... small-scale fisheries. Focusing on fisheries in Peru, the ...
... use various appendages to move across surfaces prior to ... jerky form of movement known as "twitching" motility, which ... called type IV pili, or TFP. ... a professor of bioengineering and of chemistry and biochemistry ...
Cached Biology News:Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 2Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 3Study shows small-scale fisheries' impact on marine life 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Request Info...
Biology Products: